RESYNIV

Aperçu du produit

About RESYNIV

RESYNIV is a medication containing the active ingredient Denosumab, classified as RANK Ligand Inhibitor. Denosumab, sold under the brand names Prolia and Xgeva among others, is a human monoclonal antibody used for the treatment of osteoporosis, treatment-induced bone loss, metastases to bone, and giant cell tumor of bone.

Key Benefits & Uses

• Used for: 1 INDICATIONS AND USAGE Stoboclo is a RANK ligand (RANKL) inhibitor indicated for treatment: of postmenopausal women with osteoporosis at high risk.
• Used for: 1 ) to increase bone mass in men with osteoporosis at high risk for fracture ( 1
• Use only as directed on the product label or by a healthcare professional.

Active Ingredient & Action

Denosumab, the active ingredient in RESYNIV, belongs to the RANK Ligand Inhibitor class. 1 INDICATIONS AND USAGE Stoboclo is a RANK ligand (RANKL) inhibitor indicated for treatment: of postmenopausal women with osteoporosis at high risk for fracture ( 1. 1 ) to increase bone mass in men with osteoporosis at high risk for fracture ( 1. Inactive ingredients: not listed in source data.

Important Notes

Always read and follow the label instructions carefully before taking RESYNIV. If you have any underlying medical conditions, are taking other medicines, or are pregnant or breastfeeding, consult a doctor or pharmacist before use. Do not exceed the recommended dose on the package and do not use RESYNIV for extended periods without medical advice.